Abstract.
Retrovirus-derived vectors are currently the preferred vectors used for human gene therapy protocols. Serious safety concerns persist, however, which are specifically related to the formation of a replication-competent virus, and no synthesis method currently employed precludes its formation with certainty. For many cell types, a low transduction efficiency results in insufficient therapeutic benefit. We describe the development of a molecular conjugate system, which permits transient chemical modification of a retrovirus with polylysine. This modification not only introduces additional safety features over standard unmodified retrovirus vectors, but also provides enhanced transduction efficiency.
Author information
Authors and Affiliations
Additional information
Received 25 June 2002; received after revision 16 September 2002; accepted 24 September 2002
RID="*"
ID="*"Corresponding author.
Rights and permissions
About this article
Cite this article
Zhong, Q., Kolls, J. & Schwarzenberger, P. Retrovirus molecular conjugates. CMLS, Cell. Mol. Life Sci. 59, 2083–2087 (2002). https://doi.org/10.1007/s000180200008
Issue Date:
DOI: https://doi.org/10.1007/s000180200008